Novel biomarkers for preeclampsia: Promises and pitfalls

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biomarker Discovery

Background:

• Traditional preeclampsia diagnosis relies on nonspecific clinical criteria.
• Refining diagnostic criteria has led to clinical uncertainty.
• Preeclampsia biomarkers offer potential for accurate diagnosis and risk stratification.

Purpose of the Study:

• Provide physiologic context for preeclampsia biomarkers.
• Summarize the clinical performance of novel biomarkers.
• Identify knowledge gaps hindering biomarker adoption.

Main Methods:

• Review of recent studies on angiogenic and anti-angiogenic factors.
• Analysis of laboratory assays for preeclampsia biomarkers.
• Evaluation of diagnostic concordance and predictive performance.

Main Results:

• Preeclampsia biomarkers, particularly angiogenic factors, show high diagnostic concordance.
• Biomarkers demonstrate superior prediction of adverse outcomes compared to clinical criteria.
• Widespread implementation is limited by the lack of validated intervention pathways.

Conclusions:

• Novel preeclampsia biomarkers represent significant diagnostic advances.
• Biomarkers have the potential to redefine preeclampsia diagnosis and management.
• Challenges remain in clinical adoption and pathway validation.